Federal grants to Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. in Harrison, New York received $4.1 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cancer Treatment Research, with $3.8 million. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$4.1 million
- Awards4
- Awarded in FY 2025$0
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $709,155 |
| FY 2022 | 2 | $919,785 |
| FY 2023 | 2 | $1.8 million |
| FY 2024 | 1 | $632,111 |
| FY 2025 | 0 | $0 |
Programs that fund Sapience Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 3 | $3.8 million |
| Allergy and Infectious Diseases Research | 1 | $243,934 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $4.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for wnt-driven breast cancer - abstract dysregulated overexpression and hyperactivation of wnt/-catenin signaling is found in >20% of all cancers and in 50% of breast cancer, particularly triple negative bre | Cancer Treatment Research | May 1, 2023 | $2.0 million |
| Efficacy and pk/pd of a c/ebp beta antagonist in orthotopic breast cancer - abstract breast cancer (BC) remains an immense clinical challenge, particularly for late stage and metastatic disease. Prognosis for late-stage and metastatic disease is grim, with 5-YEAR survival for stage 4 metastatic dise | Cancer Treatment Research | August 10, 2022 | $1.4 million |
| Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for wnt-driven breast cancer - abstract dysregulation of wnt/-catenin signaling is found in more than 20% of all cancers, including 50% of breast can- cers, and contributes to cancer initiation, angiogenesis | Cancer Treatment Research | September 2, 2021 | $409,295 |
| Inhibition of SARS-COV-2 infection with a pan-coronavirus anti-viral peptide - abstract the COVID-19 pandemic, caused by the SARS-COV-2 virus, is a serious threat to global public health, necessitating the rapid development of safe and effective medical countermeasures. SARS-COV-2 pathogenicity requ | Allergy and Infectious Diseases Research | May 4, 2021 | $243,934 |
Questions people ask
How much federal grant money does Sapience Therapeutics, Inc. get?
$4.1 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Sapience Therapeutics, Inc. the most?
The Department of Health and Human Services, with $4.1 million in 4 awards.
What is Sapience Therapeutics, Inc.'s largest federal grant?
$2.0 million under Cancer Treatment Research, with its first action in the period on May 1, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Sapience Therapeutics, Inc.?
Its largest are Cancer Treatment Research and Allergy and Infectious Diseases Research.
Largest federal grant recipients in New York · Federal grants in New York